Referred TestsProviding a
clear picture.
Supporting patient care
At Mayo Clinic, we offer a comprehensive approach to neuro-oncology testing that focuses on the best outcomes for the patient. Our advanced genetic testing combines molecular and cytogenetic analysis to complement standard morphological and histological assessment. This maximizes the amount of available information, and provides a clear picture of the diagnosis, prognosis, and treatment options.
A complete assessment
By performing immunohistochemical, molecular, and cytogenetic
analysis on all patients, our testing approach provides a more complete assessment of the patient’s diagnosis, prognosis, and therapy options.
Actionable answers
Broad molecular and cytogenetic information is needed for all
neuro-oncology patients in order to select the most appropriate treatment options, whether standard, off-label, or clinical trial.
A clear diagnosis
Understanding specific molecular markers is necessary to making a diagnosis that meets classification guidelines and can guide treatment decisions and therapeutic timelines.
Additional Resources
This "Specialty Testing" webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors.
At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.
Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.
Robert Jenkins, M.D., Ph.D., a pathologist and cancer geneticist at Mayo Clinic, provides an overview of the new neuro-oncology expanded gene panel and chromosomal microarray testing available through Mayo Medical Laboratories. He discusses which types of patients should be tested, how these tests improves upon previous methods, and what clinical action can be taken from the results of this testing.
Clinical studies at the Mayo Clinic have shown that this broad, but tumor-specific, genetic analysis has significant, and sometimes unexpected, clinical impact. The following case studies highlight the importance and clinical utility of these assays in diagnosis, prognosis, and therapy selection.